{"protocolSection": {"identificationModule": {"nctId": "NCT00654745", "orgStudyIdInfo": {"id": "CS-8663-403"}, "organization": {"fullName": "Daiichi Sankyo", "class": "INDUSTRY"}, "briefTitle": "18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics", "officialTitle": "A Prospective, Open-label, Ambulatory Blood Pressure Monitoring (ABPM) Dose Titration Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil and Amlodipine Based Treatment Regimen in Hypertensive, Type 2 Diabetic Subjects"}, "statusModule": {"statusVerifiedDate": "2010-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-05"}, "primaryCompletionDateStruct": {"date": "2009-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-04-04", "studyFirstSubmitQcDate": "2008-04-08", "studyFirstPostDateStruct": {"date": "2008-04-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-04-21", "resultsFirstSubmitQcDate": "2010-05-26", "resultsFirstPostDateStruct": {"date": "2010-07-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2010-07-09", "lastUpdatePostDateStruct": {"date": "2010-07-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Director, Medical Research, Hypertension", "oldOrganization": "Daiichi Sankyo Inc."}, "leadSponsor": {"name": "Daiichi Sankyo", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.", "detailedDescription": "This is a single group study in which participants were titrated to the next of 6 regimens if blood pressure (BP) goals were not met."}, "conditionsModule": {"conditions": ["Type 2 Diabetes", "Hypertension"], "keywords": ["blood pressure reduction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 207, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "aml + olm + hctz", "type": "EXPERIMENTAL", "description": "amlodipine; and olmesartan medoxomil, if required; and hydrochlorothiazide, if required.", "interventionNames": ["Drug: Amlodipine", "Drug: amlodipine / olmesartan medoxomil combination", "Drug: Hydrochlorothiazide"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine 5 mg tablets , Daily for 3 weeks;", "armGroupLabels": ["aml + olm + hctz"], "otherNames": ["Norvasc"]}, {"type": "DRUG", "name": "amlodipine / olmesartan medoxomil combination", "description": "amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg", "armGroupLabels": ["aml + olm + hctz"], "otherNames": ["Azor"]}, {"type": "DRUG", "name": "Hydrochlorothiazide", "description": "hydrochlorothiazide tablets, 12.5 mg or 25 mg.", "armGroupLabels": ["aml + olm + hctz"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment", "description": "Change from week 0 (baseline) in mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) after 12 weeks of active treatment. change = week 12 - week 0.", "timeFrame": "week 0 - week 12"}], "secondaryOutcomes": [{"measure": "Change From Week 0 (Baseline) in Mean ABPM Diastolic Blood Pressure (DBP) After 12 Weeks of Active Treatment", "description": "24-hour mean DBP, Daytime mean DBP, Nighttime mean DBP, Last 6 hour mean DBP, Last 4 hour mean DBP, Last 2 hour mean DBP", "timeFrame": "week 0 - week 12 (24-hour, Daytime, Nighttime, Last 6 hour, Last 4 hour, Last 2 hour)"}, {"measure": "Change From Week 0 (Baseline) in Mean ABPM SBP After 12 Weeks of Active Treatment", "description": "Daytime mean SBP, Nighttime mean SBP, Last 6 hour mean SBP, Last 4 hour mean SBP, Last 2 hour mean SBP", "timeFrame": "week 0 - week 12 (24-hour, Daytime, Nighttime, Last 6 hour, Last 4 hour, Last 2 hour)"}, {"measure": "Change in Mean Seated Systolic Blood Pressure (SeSBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks", "description": "change in mean SeSBP from week 0 (baseline) to Weeks 3, 6, 9, 12, 15, and 18.", "timeFrame": "week 0 - weeks 3, 6, 9, 12, 15, 18"}, {"measure": "Change in Mean Seated Diastolic Blood Pressure (SeDBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks", "description": "change in mean SeDBP from week 0 (baseline) to Weeks 3, 6, 9, 12, 15, and 18.", "timeFrame": "week 0 - weeks 3, 6, 9, 12, 15, 18"}, {"measure": "Number of Participants Achieving Mean 24-hour Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean 24-hour ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Daytime Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean daytime ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Nighttime Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean nighttime ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, BP\\<120/70, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75, DBP\\<70 at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Last 6 Hour Ambulatory Blood Pressure Thresholds at Week 12", "description": "number participants achieving mean last 6 hour ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Last 4 Hour Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean last 4 hour ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Last 2 Hour Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean last 2 hour ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 3", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 3", "timeFrame": "week 0 - week 3"}, {"measure": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 6", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 6", "timeFrame": "week 0 - week 6"}, {"measure": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 9", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 9", "timeFrame": "week 0 - week 9"}, {"measure": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 12", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 15", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 15", "timeFrame": "week 0 - week 15"}, {"measure": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 18", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 18", "timeFrame": "week 0 - week 18"}, {"measure": "Number of Participants Achieving Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean 24 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Daytime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean daytime ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Nighttime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean nighttime ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Last 6 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean last 6 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Last 4 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions", "description": "number of participants achieving mean last 4 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Last 2 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean last 2 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 3", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 3", "timeFrame": "week 0 - week 3"}, {"measure": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 6", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 6", "timeFrame": "week 0 - week 6"}, {"measure": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 9", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 9", "timeFrame": "week 0 - week 9"}, {"measure": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "timeFrame": "week 0 - week 12"}, {"measure": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 15", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 15", "timeFrame": "week 0 - week 15"}, {"measure": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 18", "timeFrame": "week 0 - week 18"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Males or females aged 18 to 80 years.\n* Diagnosis of type 2 diabetes mellitus and on a stable regimen of any oral antidiabetic agent(s) for at least 3 months, with or without adjunctive use of Byetta (exenatide);\n\nNote: Subjects diagnosed with type 2 diabetes mellitus who were not on oral antidiabetic agents may have been enrolled if they had a documented history of type 2 diabetes by American Diabetes Association criteria, including the specific plasma glucose results listed below:\n\n* Fasting plasma glucose \\>=126 mg/dL (7.0 mmol/L); or\n* Symptoms of hyperglycemia and a casual (any time of day without regard to time since last meal) plasma glucose \\>=200 mg/dL (11.1 mmol/L). The classic symptoms of hyperglycemia were considered to include polyuria, polydipsia, and unexplained weight loss; or\n* Two-hour plasma glucose \\>=200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test;\n* Newly diagnosed hypertension or uncontrolled hypertension (defined as SBP \\>130 mmHg and/or DBP \\>80 mmHg) on current antihypertensive monotherapy or combination therapy.\n* Subjects must fulfill mean seated office blood pressure parameters at two consecutive, qualifying visits during the placebo run-in phase, and, subsequently, daytime ambulatory blood pressure monitoring (ABPM) criteria.\n* Females should not be pregnant or lactating and, if applicable, using adequate contraception.\n\nExclusion Criteria:\n\n* Subjects with uncontrolled hypertension taking multiple antihypertensive therapies (at the discretion of the investigator).\n* Type 2 diabetes mellitus with a glycosylated hemoglobin A1c (HbA1c) \\>=9.0% at screening;\n* Subjects with type 1 or type 2 diabetes mellitus requiring insulin.\n* Subjects with any serious disorder which may limit the ability to evaluate the safety and efficacy of study medication, or subjects with secondary hypertension.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"city": "Sylmar", "state": "California", "country": "United States", "geoPoint": {"lat": 34.30778, "lon": -118.44925}}, {"city": "Tustin", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"city": "Aventura", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.95648, "lon": -80.13921}}, {"city": "DeLand", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.02832, "lon": -81.30312}}, {"city": "Hialeah", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"city": "Pembroke Pines", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"city": "Avon", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 39.76282, "lon": -86.39972}}, {"city": "Indianapolis", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"city": "Las Vegas", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"city": "New Windsor", "state": "New York", "country": "United States", "geoPoint": {"lat": 41.47676, "lon": -74.02375}}, {"city": "Winston-Salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"city": "Greer", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"city": "Taylors", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.92039, "lon": -82.29623}}, {"city": "Nashville", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"city": "Burke", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.79345, "lon": -77.27165}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects began washout of anti-hypertensive medications during screening then entered placebo run-in lasting 2-3 weeks. Subjects must meet seated blood pressure (BP) criteria at 2 consecutive qualifying visits during the run-in period and satisfy mean daytime ambulatory BP criteria at baseline, one day prior to the first dose of active study drug.", "recruitmentDetails": "Subjects were recruited at 32 sites in the USA from May 12, 2008 to Jan 2, 2009 and 207 enrolled into the active treatment period. The study population consisted of subjects with controlled type 2 diabetes, not requiring insulin therapy, whose hypertension was newly diagnosed or uncontrolled on antihypertensive monotherapy or combination therapy.", "groups": [{"id": "FG000", "title": "Amlodipine, Olmesartan Medoxomil, Hydrochlorothiazide", "description": "Participants receiving amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "This is single group study in which subjects were titrated to the next of 7 arms if BP goal not met.", "numSubjects": "207"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "164"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "43"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "12"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "11"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}]}, {"type": "poor ABPM, noncompliance, lab MAs", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aml + Olm + Hctz", "description": "amlodipine (aml) + olmesartan medoxomil (olm)+ hhdrochlorothiazide (hctz) is total number enrolled. Each group is the number of participants that were titrated to that dosing regimen as per the protocol. The total number of participants of the individual groups does not (and should not) equal the total number enrolled."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "207"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.1", "spread": "9.50"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "122"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "85"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "54"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "153"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "35"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "162"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Stage of hypertension", "description": "Stage 1 or Stage 2 Hypertension. Stage 1 = Blood pressure \\> 140/90 mm Hg. Stage 2 = systolic \\>160 mm Hg or diastolic \\> 100 mm Hg", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Stage 1", "categories": [{"measurements": [{"groupId": "BG000", "value": "115"}]}]}, {"title": "Stage 2", "categories": [{"measurements": [{"groupId": "BG000", "value": "92"}]}]}]}, {"title": "Body mass index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.80", "spread": "5.947"}]}]}]}, {"title": "Mean 24-hour ambulatory diastolic blood pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "81.6", "spread": "9.76"}]}]}]}, {"title": "Mean 24-hour ambulatory systolic blood pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "144.4", "spread": "11.74"}]}]}]}, {"title": "Pulse rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "beats per minute", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "73.75", "spread": "11.909"}]}]}]}, {"title": "Seated Diastolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "89.1", "spread": "10.13"}]}]}]}, {"title": "Seated Systolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "158.8", "spread": "13.14"}]}]}]}, {"title": "Years with diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.44", "spread": "5.978"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment", "description": "Change from week 0 (baseline) in mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) after 12 weeks of active treatment. change = week 12 - week 0.", "populationDescription": "ABPM subjects analysis population included 165 subjects who received at least one dose of active study medication and provided valid ambulatory blood pressure monitoring measurements at baseline and week 12.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.9", "spread": "0.76"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-19.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.5", "ciUpperLimit": "-18.4"}]}, {"type": "SECONDARY", "title": "Change From Week 0 (Baseline) in Mean ABPM Diastolic Blood Pressure (DBP) After 12 Weeks of Active Treatment", "description": "24-hour mean DBP, Daytime mean DBP, Nighttime mean DBP, Last 6 hour mean DBP, Last 4 hour mean DBP, Last 2 hour mean DBP", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "week 0 - week 12 (24-hour, Daytime, Nighttime, Last 6 hour, Last 4 hour, Last 2 hour)", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "24-hour mean DBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.2", "spread": "0.50"}]}]}, {"title": "daytime mean DBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.7", "spread": "0.60"}]}]}, {"title": "nighttime mean DBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.4", "spread": "0.68"}]}]}, {"title": "last 6 hour mean DBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.9", "spread": "0.64"}]}]}, {"title": "last 4 hour mean DBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.1", "spread": "0.68"}]}]}, {"title": "last 2 hour mean DBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.5", "spread": "0.76"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "24-hour mean DBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-11.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.2", "ciUpperLimit": "-10.3"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "daytime mean DBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-11.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.9", "ciUpperLimit": "-10.5"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "nighttime mean DBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-10.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.7", "ciUpperLimit": "-9.0"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "last 6 hours mean DBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-10.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.2", "ciUpperLimit": "-9.7"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "last 4 hours mean DBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-11.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.4", "ciUpperLimit": "-9.8"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "last 2 hours mean DBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-11.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.1", "ciUpperLimit": "-10.0"}]}, {"type": "SECONDARY", "title": "Change From Week 0 (Baseline) in Mean ABPM SBP After 12 Weeks of Active Treatment", "description": "Daytime mean SBP, Nighttime mean SBP, Last 6 hour mean SBP, Last 4 hour mean SBP, Last 2 hour mean SBP", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "week 0 - week 12 (24-hour, Daytime, Nighttime, Last 6 hour, Last 4 hour, Last 2 hour)", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "daytime mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.8", "spread": "0.92"}]}]}, {"title": "nighttime mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.5", "spread": "0.95"}]}]}, {"title": "last 6 hours mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-18.9", "spread": "0.93"}]}]}, {"title": "last 4 hours mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.1", "spread": "1.02"}]}]}, {"title": "last 2 hours mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.5", "spread": "1.10"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "daytime mean SBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-20.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.6", "ciUpperLimit": "-18.9"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "nighttime mean SBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-18.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.4", "ciUpperLimit": "-16.6"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "last 6 hours mean SBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-18.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.7", "ciUpperLimit": "-17.0"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "last 4 hours mean SBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-19.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.1", "ciUpperLimit": "-17.1"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline to week12 in ABPM is 0. Change from baseline to week12 is primary efficacy variable and used all ABPM subjects. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "last 2 hours mean SBP change from baseline to week 12.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with 164 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-19.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.7", "ciUpperLimit": "-17.4"}]}, {"type": "SECONDARY", "title": "Change in Mean Seated Systolic Blood Pressure (SeSBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks", "description": "change in mean SeSBP from week 0 (baseline) to Weeks 3, 6, 9, 12, 15, and 18.", "populationDescription": "Number of participants changed by week. Week 3 = 201, Week 6 = 192, week 9 = 184, week 12 = 177, week 15 = 172, week 18 = 164.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "week 0 - weeks 3, 6, 9, 12, 15, 18", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}]}], "classes": [{"title": "week 3 mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.3", "spread": "0.87"}]}]}, {"title": "week 6 mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.9", "spread": "0.92"}]}]}, {"title": "week 9 mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.0", "spread": "1.10"}]}]}, {"title": "week 12 mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.7", "spread": "1.02"}]}]}, {"title": "week 15 mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.5", "spread": "1.16"}]}]}, {"title": "week 18 mean SBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.1", "spread": "1.13"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated systolic blood pressure from baseline to week 3.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-10.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.0", "ciUpperLimit": "-8.6"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated systolic blood pressure from baseline to week 6.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-17.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.8", "ciUpperLimit": "-16.1"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated systolic blood pressure from baseline to week 9", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-20.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.2", "ciUpperLimit": "-17.8"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated systolic blood pressure from baseline to week 12", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-23.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.7", "ciUpperLimit": "-21.7"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated systolic blood pressure from baseline to week 15", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-28.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.8", "ciUpperLimit": "-26.2"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated systolic blood pressure from baseline to week 18", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-31.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.3", "ciUpperLimit": "-28.8"}]}, {"type": "SECONDARY", "title": "Change in Mean Seated Diastolic Blood Pressure (SeDBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks", "description": "change in mean SeDBP from week 0 (baseline) to Weeks 3, 6, 9, 12, 15, and 18.", "populationDescription": "Number of participants changed by week. Week 3 = 201, Week 6 = 192, week 9 = 184, week 12 = 177, week 15 = 172, week 18 = 164.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "week 0 - weeks 3, 6, 9, 12, 15, 18", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}]}], "classes": [{"title": "week 3 mean seDBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.1", "spread": "0.50"}]}]}, {"title": "week 6 mean seDBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.2", "spread": "0.60"}]}]}, {"title": "week 9 mean seDBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.7", "spread": "0.64"}]}]}, {"title": "week 12 mean seDBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.2", "spread": "0.64"}]}]}, {"title": "week 15 mean seDBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.4", "spread": "0.66"}]}]}, {"title": "week 18 mean seDBP change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.1", "spread": "0.72"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated diastolic blood pressure from baseline to week 3.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-4.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.1", "ciUpperLimit": "-3.1"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated diastolic blood pressure from baseline to week 6", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-8.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.4", "ciUpperLimit": "-7.1"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated diastolic blood pressure from baseline to week 9", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-9.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.9", "ciUpperLimit": "-8.4"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated diastolic blood pressure from baseline to week 12", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-11.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.5", "ciUpperLimit": "-9.9"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated diastolic blood pressure from baseline to week 15", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-14.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.7", "ciUpperLimit": "-13.1"}, {"groupIds": ["OG000"], "groupDescription": "Primary null hypothesis is change from baseline is 0. Null hypothesis used 1-sample t-test on change. Sample size of 200 expected to provide 99% power at significance level of 0.05%.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Change in mean seated diastolic blood pressure from baseline to week 18", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "standard 1-sample confidence interval construction using t-distribution with n-1 degrees of freedom", "paramType": "Mean Difference (Net)", "paramValue": "-15.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.5", "ciUpperLimit": "-13.6"}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean 24-hour Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean 24-hour ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean 24-hour BP <135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "140"}]}]}, {"title": "mean 24-hour BP <130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "116"}]}]}, {"title": "mean 24-hour BP <125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}]}]}, {"title": "mean 24-hour BP <120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "59"}]}]}, {"title": "mean 24-hour SBP <135", "categories": [{"measurements": [{"groupId": "OG000", "value": "140"}]}]}, {"title": "mean 24-hour SBP <130", "categories": [{"measurements": [{"groupId": "OG000", "value": "120"}]}]}, {"title": "mean 24-hour SBP <125", "categories": [{"measurements": [{"groupId": "OG000", "value": "92"}]}]}, {"title": "mean 24-hour SBP <120", "categories": [{"measurements": [{"groupId": "OG000", "value": "59"}]}]}, {"title": "mean 24-hour DBP <85", "categories": [{"measurements": [{"groupId": "OG000", "value": "158"}]}]}, {"title": "mean 24-hour DBP <80", "categories": [{"measurements": [{"groupId": "OG000", "value": "146"}]}]}, {"title": "mean 24-hour DBP <75", "categories": [{"measurements": [{"groupId": "OG000", "value": "121"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Daytime Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean daytime ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean daytime BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "116"}]}]}, {"title": "mean daytime BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "83"}]}]}, {"title": "mean daytime BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "48"}]}]}, {"title": "mean daytime BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}]}]}, {"title": "mean daytime SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "118"}]}]}, {"title": "mean daytime SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}]}]}, {"title": "mean daytime SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "67"}]}]}, {"title": "mean daytime SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}]}]}, {"title": "mean daytime DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "151"}]}]}, {"title": "mean daytime DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "124"}]}]}, {"title": "mean daytime DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "91"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Nighttime Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean nighttime ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, BP\\<120/70, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75, DBP\\<70 at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean nighttime BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "152"}]}]}, {"title": "mean nighttime BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "137"}]}]}, {"title": "mean nighttime BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "119"}]}]}, {"title": "mean nighttime BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "112"}]}]}, {"title": "mean nighttime BP < 120/70", "categories": [{"measurements": [{"groupId": "OG000", "value": "101"}]}]}, {"title": "mean nighttime SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}]}]}, {"title": "mean nighttime SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "139"}]}]}, {"title": "mean nighttime SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "123"}]}]}, {"title": "mean nighttime SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "112"}]}]}, {"title": "mean nighttime DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "160"}]}]}, {"title": "mean nighttime DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "158"}]}]}, {"title": "mean nighttime DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "147"}]}]}, {"title": "mean nighttime DBP < 70", "categories": [{"measurements": [{"groupId": "OG000", "value": "124"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Last 6 Hour Ambulatory Blood Pressure Thresholds at Week 12", "description": "number participants achieving mean last 6 hour ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean last 6 hour BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "135"}]}]}, {"title": "mean last 6 hour BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "124"}]}]}, {"title": "mean last 6 hour BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "101"}]}]}, {"title": "mean last 6 hour BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "85"}]}]}, {"title": "mean last 6 hour SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "143"}]}]}, {"title": "mean last 6 hour SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "127"}]}]}, {"title": "mean last 6 hour SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "108"}]}]}, {"title": "mean last 6 hour SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "85"}]}]}, {"title": "mean last 6 hour DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "157"}]}]}, {"title": "mean last 6 hour DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "146"}]}]}, {"title": "mean last 6 hour DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "130"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Last 4 Hour Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean last 4 hour ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean last 4 hour BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "129"}]}]}, {"title": "mean last 4 hour BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "107"}]}]}, {"title": "mean last 4 hour BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "92"}]}]}, {"title": "mean last 4 hour BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "72"}]}]}, {"title": "mean last 4 hour SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "131"}]}]}, {"title": "mean last 4 hour SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "114"}]}]}, {"title": "mean last 4 hour SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "102"}]}]}, {"title": "mean last 4 hour SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "72"}]}]}, {"title": "mean last 4 hour DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "150"}]}]}, {"title": "mean last 4 hour DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "137"}]}]}, {"title": "mean last 4 hour DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "120"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Last 2 Hour Ambulatory Blood Pressure Thresholds at Week 12", "description": "number of participants achieving mean last 2 hour ambulatory blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean last 2 hour BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "110"}]}]}, {"title": "mean last 2 hour BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "85"}]}]}, {"title": "mean last 2 hour BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "63"}]}]}, {"title": "mean last 2 hour BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}]}]}, {"title": "mean last 2 hour SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "115"}]}]}, {"title": "mean last 2 hour SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "92"}]}]}, {"title": "mean last 2 hour SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}]}]}, {"title": "mean last 2 hour SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}]}]}, {"title": "mean last 2 hour DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "145"}]}]}, {"title": "mean last 2 hour DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "125"}]}]}, {"title": "mean last 2 hour DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 3", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 3", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 3", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}]}], "classes": [{"title": "mean BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}, {"title": "mean BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "mean BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "mean BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "mean SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}]}]}, {"title": "mean SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}]}]}, {"title": "mean SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "mean SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "mean DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "99"}]}]}, {"title": "mean DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "58"}]}]}, {"title": "mean DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 6", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 6", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 6", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}]}], "classes": [{"title": "mean BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "61"}]}]}, {"title": "mean BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}]}]}, {"title": "mean BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}]}]}, {"title": "mean BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}]}]}, {"title": "mean SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "73"}]}]}, {"title": "mean SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "48"}]}]}, {"title": "mean SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}, {"title": "mean SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}]}]}, {"title": "mean DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "127"}]}]}, {"title": "mean DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "91"}]}]}, {"title": "mean DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "48"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 9", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 9", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 9", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}]}], "classes": [{"title": "mean BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}]}]}, {"title": "mean BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}]}]}, {"title": "mean BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}, {"title": "mean BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}]}]}, {"title": "mean SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "82"}]}]}, {"title": "mean SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "61"}]}]}, {"title": "mean SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}]}]}, {"title": "mean SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}]}]}, {"title": "mean DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "132"}]}]}, {"title": "mean DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "95"}]}]}, {"title": "mean DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "64"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 12", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "177"}]}], "classes": [{"title": "mean BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "86"}]}]}, {"title": "mean BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "61"}]}]}, {"title": "mean BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}]}]}, {"title": "mean BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}]}]}, {"title": "mean SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "93"}]}]}, {"title": "mean SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "70"}]}]}, {"title": "mean SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}]}]}, {"title": "mean SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}]}]}, {"title": "mean DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "134"}]}]}, {"title": "mean DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "105"}]}]}, {"title": "mean DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "74"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 15", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 15", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 15", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}]}], "classes": [{"title": "mean BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "114"}]}]}, {"title": "mean BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "83"}]}]}, {"title": "mean BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}]}]}, {"title": "mean BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}]}]}, {"title": "mean SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "116"}]}]}, {"title": "mean SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "95"}]}]}, {"title": "mean SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "69"}]}]}, {"title": "mean SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "48"}]}]}, {"title": "mean DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "153"}]}]}, {"title": "mean DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "122"}]}]}, {"title": "mean DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "96"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 18", "description": "number of participants achieving seated systolic and diastolic blood pressure thresholds BP\\<135/85, BP\\<130/80, BP\\<125/75, BP\\<120/80, SBP\\<135, SBP\\<130, SBP\\<125, SBP\\<120, DBP\\<85, DBP\\<80, DBP\\<75 at week 18", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 18", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}]}], "classes": [{"title": "mean BP < 135/85", "categories": [{"measurements": [{"groupId": "OG000", "value": "117"}]}]}, {"title": "mean BP < 130/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "87"}]}]}, {"title": "mean BP < 125/75", "categories": [{"measurements": [{"groupId": "OG000", "value": "56"}]}]}, {"title": "mean BP < 120/80", "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}]}]}, {"title": "mean SBP < 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "123"}]}]}, {"title": "mean SBP < 130", "categories": [{"measurements": [{"groupId": "OG000", "value": "101"}]}]}, {"title": "mean SBP < 125", "categories": [{"measurements": [{"groupId": "OG000", "value": "74"}]}]}, {"title": "mean SBP < 120", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}]}]}, {"title": "mean DBP < 85", "categories": [{"measurements": [{"groupId": "OG000", "value": "147"}]}]}, {"title": "mean DBP < 80", "categories": [{"measurements": [{"groupId": "OG000", "value": "128"}]}]}, {"title": "mean DBP < 75", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean 24 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean 24-hour SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "50"}]}]}, {"title": "mean 24-hour SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "91"}]}]}, {"title": "mean 24-hour SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}]}]}, {"title": "mean 24-hour SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "mean 24-hour DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "72"}]}]}, {"title": "mean 24-hour DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}]}]}, {"title": "mean 24-hour DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}, {"title": "mean 24-hour DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Daytime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean daytime ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean daytime SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}]}]}, {"title": "mean daytime SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "84"}]}]}, {"title": "mean daytime SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}, {"title": "mean daytime SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "mean daytime DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "68"}]}]}, {"title": "mean daytime DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}]}]}, {"title": "mean daytime DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}]}]}, {"title": "mean daytime DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Nighttime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean nighttime ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean nighttime SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "60"}]}]}, {"title": "mean nighttime SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "79"}]}]}, {"title": "mean nighttime SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}]}]}, {"title": "mean nighttime SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "mean nighttime DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "80"}]}]}, {"title": "mean nighttime SBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}]}]}, {"title": "mean nighttime SBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}]}]}, {"title": "mean nighttime DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Last 6 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean last 6 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean last 6 hour SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "61"}]}]}, {"title": "mean last 6 hour SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}]}]}, {"title": "mean last 6 hour SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}, {"title": "mean last 6 hour SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "mean last 6 hour DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}]}]}, {"title": "mean last 6 hour DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}]}]}, {"title": "mean last 6 hour DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}]}]}, {"title": "mean last 6 hour DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Last 4 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions", "description": "number of participants achieving mean last 4 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean last 4 hour SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "67"}]}]}, {"title": "mean last 4 hour SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "65"}]}]}, {"title": "mean last 4 hour SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}]}]}, {"title": "mean last 4 hour SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "mean last 4 hour DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}]}]}, {"title": "mean last 4 hour DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}]}]}, {"title": "mean last 4 hour DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}, {"title": "mean last 4 hour DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Last 2 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean last 2 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}]}], "classes": [{"title": "mean last 2 hour SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "63"}]}]}, {"title": "mean last 2 hour SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}]}]}, {"title": "mean last 2 hour SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}]}]}, {"title": "mean last 2 hour SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "mean last 2 hour DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "77"}]}]}, {"title": "mean last 2 hour DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}]}]}, {"title": "mean last 2 hour DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}]}]}, {"title": "mean last 2 hour DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 3", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 3", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 3", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}]}], "classes": [{"title": "mean seated SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "131"}]}]}, {"title": "mean seated SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}]}]}, {"title": "mean seated SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}, {"title": "mean seated SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "mean seated DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "163"}]}]}, {"title": "mean seated DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}, {"title": "mean seated DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "mean seated DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 6", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 6", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 6", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}]}], "classes": [{"title": "mean seated SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "69"}]}]}, {"title": "mean seated SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "90"}]}]}, {"title": "mean seated SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}, {"title": "mean seated SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "mean seated DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "120"}]}]}, {"title": "mean seated DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}]}]}, {"title": "mean seated DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}]}]}, {"title": "mean seated DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 9", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 9", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 9", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}]}], "classes": [{"title": "mean seated SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "72"}]}]}, {"title": "mean seated SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "69"}]}]}, {"title": "mean seated SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "34"}]}]}, {"title": "mean seated SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "mean seated DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}]}]}, {"title": "mean seated DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "43"}]}]}, {"title": "mean seated DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}]}]}, {"title": "mean seated DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 12", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 12", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 12", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "177"}]}], "classes": [{"title": "mean seated SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "48"}]}]}, {"title": "mean seated SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "73"}]}]}, {"title": "mean seated SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}]}]}, {"title": "mean seated SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "mean seated DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "85"}]}]}, {"title": "mean seated DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}]}]}, {"title": "mean seated DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}]}]}, {"title": "mean seated DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 15", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 15", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 15", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}]}], "classes": [{"title": "mean seated SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}, {"title": "mean seated SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "66"}]}]}, {"title": "mean seated SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}]}]}, {"title": "mean seated SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}]}]}, {"title": "mean seated DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "52"}]}]}, {"title": "mean seated DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}]}]}, {"title": "mean seated DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}]}]}, {"title": "mean seated DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "43"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18", "description": "number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction \\<= 15 mmHg, SBP reduction \\> 15 mmHg \\& \\<= 30 mmHg, SBP reduction \\> 30 mmHg \\& \\<= 45 mmHg, SBP reduction \\> 45 mmHg, DBP reduction \\<= 10 mmHg, DBP reduction \\> 10 mmHg \\& \\<= 15 mmHg, DBP reduction \\> 15 mmHg \\& \\<= 20 mmHg, DBP reduction \\> 20 mmHg at week 18", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "week 0 - week 18", "groups": [{"id": "OG000", "title": "Aml + Olm + Hctz", "description": "amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}]}], "classes": [{"title": "mean seated SBP reduction =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}]}]}, {"title": "mean seated SBP reduction >15 & =<30 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}]}]}, {"title": "mean seated SBP reduction >30 & =<45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "64"}]}]}, {"title": "mean seated SBP reduction >45 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}, {"title": "mean seated DBP reduction =<10 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "50"}]}]}, {"title": "mean seated DBP reduction >10 & =<15 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}]}]}, {"title": "mean seated DBP reduction >15 & =<20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}]}]}, {"title": "mean seated DBP reduction >20 mm Hg", "categories": [{"measurements": [{"groupId": "OG000", "value": "52"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "ALL - Aml + Olm + Hctz", "description": "Summary of ALL participants receiving amlodipine + olmesartan medoxomil, if required, + hydrochlorothiazide, if required", "seriousNumAffected": 4, "seriousNumAtRisk": 207, "otherNumAffected": 80, "otherNumAtRisk": 207}, {"id": "EG001", "title": "Start - Amlodipine 5 mg", "description": "All participants started trial on Amlodipine 5 mg.", "seriousNumAffected": 0, "seriousNumAtRisk": 207, "otherNumAffected": 16, "otherNumAtRisk": 207}, {"id": "EG002", "title": "Titration 1 - Amlodipine 5 mg / Olmesartan 20 mg", "description": "Participants not meeting blood pressure (BP) goals on previous regimen were titrated to this regimen.", "seriousNumAffected": 0, "seriousNumAtRisk": 195, "otherNumAffected": 15, "otherNumAtRisk": 195}, {"id": "EG003", "title": "Titration 2 - Amlodipine 5 mg / Olmesartan 40 mg", "description": "Participants not meeting blood pressure (BP) goals on previous regimen were titrated to this regimen.", "seriousNumAffected": 1, "seriousNumAtRisk": 177, "otherNumAffected": 10, "otherNumAtRisk": 177}, {"id": "EG004", "title": "Titration 3 - Amlodipine 10 mg / Olmesartan 40 mg", "description": "Participants not meeting blood pressure (BP) goals on previous regimen were titrated to this regimen.", "seriousNumAffected": 0, "seriousNumAtRisk": 167, "otherNumAffected": 21, "otherNumAtRisk": 167}, {"id": "EG005", "title": "Titration 4 Amlodipine 10 mg / Olmesartan 40 mg / HCTZ 12.5 mg", "description": "Participants not meeting blood pressure (BP) goals on previous regimen were titrated to this regimen.", "seriousNumAffected": 1, "seriousNumAtRisk": 146, "otherNumAffected": 14, "otherNumAtRisk": 146}, {"id": "EG006", "title": "Titration 5 - Amlodipine 10 mg / Olmesartan 40 mg / HCTZ 25 mg", "description": "Participants not meeting blood pressure (BP) goals on previous regimen were titrated to this regimen.", "seriousNumAffected": 2, "seriousNumAtRisk": 101, "otherNumAffected": 4, "otherNumAtRisk": 101}], "seriousEvents": [{"term": "pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}]}, {"term": "hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}, {"term": "presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}, {"term": "chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}]}], "otherEvents": [{"term": "anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 101}]}, {"term": "oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 20, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 7, "numAffected": 7, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}, {"term": "upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 3, "numAffected": 3, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}, {"term": "bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}, {"term": "pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}, {"term": "arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}, {"term": "dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 12, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 5, "numAffected": 5, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}, {"term": "headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}]}, {"term": "cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}]}, {"term": "hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 207}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 195}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 177}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 146}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor reflects the following restrictive language in the Clinical Study Agreements: \"If identified by Daiichi Sankyo Inc. (DSI), any of DSI's confidential information as defined herein shall be deleted. Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by the Study Site.\""}, "pointOfContact": {"title": "James McCarthy", "organization": "Daiichi Sankyo", "email": "jmccarthy@dsi.com", "phone": "732-590-3430"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000437965", "term": "Olmesartan"}, {"id": "D000068557", "term": "Olmesartan Medoxomil"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M91890", "name": "Olmesartan", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M273", "name": "Olmesartan Medoxomil", "asFound": "Sleep hygiene", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}